Multi-Peptide Protocol

GH Secretagogue Stack: CJC-1295 + Ipamorelin

These compounds are research chemicals. CJC-1295 and Ipamorelin are not FDA-approved for human use. This protocol is for educational purposes only.
Contraindications — Do Not Use If:

Active cancer or history of cancer. Growth hormone promotes cell proliferation and angiogenesis. GH secretagogues may accelerate tumor growth or recurrence in individuals with active or prior malignancies.[1]

Diabetic retinopathy. Elevated GH and IGF-1 levels are associated with progression of diabetic retinopathy due to retinal angiogenesis.[2]

Intracranial hypertension. GH therapy has been associated with pseudotumor cerebri (benign intracranial hypertension), particularly in early treatment phases.

Known hypersensitivity to GHRPs or GHRH analogs. Allergic reactions, although rare, have been reported with peptide injections.

Pregnancy or breastfeeding. No reproductive toxicology data exist for CJC-1295 or Ipamorelin in humans. GH axis manipulation during pregnancy is contraindicated.

Children and adolescents with open growth plates. Supraphysiological GH stimulation may cause premature closure of growth plates or disproportionate growth. Only supervised pediatric endocrinology should manage GH disorders in children.

Combination Not Clinically Studied in Long-term Trials

While CJC-1295 and Ipamorelin have each been studied individually in short-duration human trials, their combination has not been evaluated in any published long-term clinical trial. The rationale for combining them is based on their complementary mechanisms of action on the GH axis. Long-term safety data for concurrent use are absent, and all protocols should be monitored by a qualified clinician.

Rationale for Combination

CJC-1295 and Ipamorelin are combined because they stimulate growth hormone release through two distinct and complementary receptor pathways. When used together, they produce a synergistic amplification of pulsatile GH secretion that exceeds what either compound achieves alone.

CJC-1295: Modified GHRH Analog

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH, a.k.a. GRF 1–29) with modifications that dramatically extend its half-life. Its key pharmacological features include:

  • Drug Affinity Complex (DAC): The DAC modification allows CJC-1295 to bind albumin in vivo, extending its half-life from minutes (native GHRH) to approximately 6–8 days. This produces sustained, pulsatile GH elevation over the dosing interval rather than a single acute spike.[3]
  • Pulsatile GH release: Unlike exogenous GH injection, CJC-1295 preserves the physiological pulsatile pattern of GH secretion by stimulating the GHRH receptor (GHRH-R) on pituitary somatotrophs. This is considered more favorable than continuous GH elevation for maintaining receptor sensitivity.[4]
  • IGF-1 elevation: In a dose-escalation study, CJC-1295 with DAC produced 1.5–3-fold increases in IGF-1 levels sustained for 6–14 days following a single injection.[3]
  • Non-DAC variant (Mod GRF 1–29): The version without DAC has a shorter half-life (~30 minutes) and requires daily dosing. It produces more discrete GH pulses, which some practitioners prefer for tighter control.[5]

Ipamorelin: Selective Ghrelin Mimetic

Ipamorelin is a pentapeptide growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. It is considered the most selective GHRP (growth hormone-releasing peptide) available:

  • Selective GH release: Unlike other ghrelin mimetics (GHRP-6, GHRP-2, hexarelin), Ipamorelin stimulates GH release without significantly raising cortisol, prolactin, or ACTH at therapeutic doses. This selectivity profile was demonstrated in multiple preclinical and clinical studies.[6][7]
  • Dose-dependent GH release: Ipamorelin produces a linear, dose-dependent increase in GH secretion, making it predictable and titratable.[6]
  • Ghrelin receptor activation: By acting on GHS-R1a, Ipamorelin works through a pathway complementary to GHRH. The GHRP pathway amplifies the GH pulse initiated by GHRH stimulation.[8]
  • No tachyphylaxis at standard doses: In a porcine model, Ipamorelin maintained GH-releasing efficacy over a sustained infusion period without desensitization.[7]

Synergistic Mechanism

The combination exploits the well-documented synergy between the GHRH and GHRP signaling pathways. GHRH primes the somatotroph by increasing intracellular cAMP, while GHRPs (acting via the ghrelin receptor) potentiate this through a PKC-mediated pathway. When both pathways are activated simultaneously, the resulting GH pulse amplitude is significantly greater than the additive effect of either pathway alone.[8][9]

Per-Component Dosing

The following dosing information reflects commonly reported protocols in the research and clinical compounding literature. Individual responses vary significantly, and dosing should always be guided by a supervising clinician with IGF-1 monitoring.

Parameter CJC-1295 (with DAC) CJC-1295 (no DAC / Mod GRF) Ipamorelin
Typical dose 100 mcg 100 mcg 100 – 300 mcg
Frequency 2–3× per week 1–3× daily 1–3× daily
Route Subcutaneous Subcutaneous Subcutaneous
Half-life ~6–8 days ~30 minutes ~2 hours
Timing Any time (long-acting) Before bed, empty stomach Before bed, empty stomach
Reconstitution Bacteriostatic water Bacteriostatic water Bacteriostatic water
Storage Refrigerated (2–8 °C) Refrigerated (2–8 °C) Refrigerated (2–8 °C)
Timing Note

For optimal GH pulse amplitude, inject on an empty stomach (at least 2 hours after eating) and avoid food for 30–60 minutes post-injection. Before bed is the ideal timing, as it synergizes with the natural nocturnal GH surge. A secondary morning fasted dose may be added for those using 2–3× daily protocols. Avoid dosing within 1 hour of high-glycemic meals, as insulin blunts GH release.

Cycle Structure

Loading Phase (Weeks 1–4)

  • CJC-1295 (with DAC): 100 mcg subcutaneously 2–3× per week; or CJC-1295 (no DAC): 100 mcg subcutaneously 1–3× daily
  • Ipamorelin: 100–200 mcg subcutaneously 1–3× daily (start at 100 mcg once daily before bed; titrate up based on response and tolerance)
  • Daily dosing during this phase saturates the GH axis and establishes baseline IGF-1 elevation
  • Draw baseline labs before starting: IGF-1, fasting glucose, fasting insulin, HbA1c, comprehensive metabolic panel

Maintenance Phase (Weeks 5–12)

  • CJC-1295 (with DAC): 100 mcg subcutaneously 1–2× per week; or CJC-1295 (no DAC): 100 mcg subcutaneously once daily
  • Ipamorelin: 100–200 mcg subcutaneously once daily before bed
  • Reduce frequency to the minimum effective dose that maintains target IGF-1 levels in the upper-normal range
  • Recheck IGF-1 and fasting glucose at week 6 and week 12

Off-Cycle

  • After 12 weeks, discontinue both compounds for 4–8 weeks
  • The off-cycle period allows GH receptor sensitivity to normalize and prevents sustained supraphysiological IGF-1 levels
  • Long-term continuous use has not been studied and is not recommended
  • Recheck IGF-1 during the off-cycle (at week 2–4 off) to confirm return to baseline

Timing & Administration

  • Empty stomach required: Inject at least 2 hours after the last meal. Food, particularly carbohydrates, triggers insulin release which suppresses GH secretion.
  • Before bed is ideal: The largest natural GH pulse occurs during the first 90 minutes of deep sleep (slow-wave sleep). Injecting 15–30 minutes before bed synergizes with this endogenous pulse for maximum amplitude.[10]
  • Morning fasted dose (optional): A secondary dose upon waking (before breakfast) can be added for those on multi-dose protocols. Wait at least 30 minutes before eating.
  • Injection technique: Subcutaneous injection into the abdominal fat pad, rotating sites. Use a 29–31 gauge insulin syringe. No need to inject near any specific body part (systemic effect).
  • Do not mix in the same syringe unless validated: While some practitioners combine CJC-1295 and Ipamorelin in a single syringe, chemical compatibility has not been formally studied. Use separate syringes if in doubt.

Monitoring Guidance

GH secretagogues require careful monitoring because sustained GH/IGF-1 elevation carries metabolic consequences. All users should be under clinician supervision with regular lab work.

What to Track

  • IGF-1 levels (primary marker): Target the upper-normal reference range (ideally 200–300 ng/mL for adults, lab-specific). Supraphysiological IGF-1 (>350 ng/mL) increases the risk of adverse effects and should trigger dose reduction. Check at baseline, week 4, week 8, and week 12.[1]
  • Fasting glucose and fasting insulin: GH impairs glucose tolerance by promoting hepatic gluconeogenesis and reducing peripheral insulin sensitivity. Monitor at baseline and every 4 weeks.[2]
  • HbA1c: Check at baseline and at protocol completion to assess cumulative glycemic impact over the cycle.
  • Cortisol: While Ipamorelin is selective, high doses or combination effects may influence cortisol. Check morning cortisol if symptoms of adrenal excess or insufficiency develop.
  • Joint and edema assessment: GH can cause water retention, carpal tunnel-like symptoms, and joint stiffness. Document and track weekly.
  • Body composition: DEXA or bioimpedance at baseline and protocol end to objectively track lean mass and fat mass changes.
  • Sleep quality: GH secretagogues may improve deep sleep. Track subjective sleep quality with a standardized questionnaire.

When to Stop

  • IGF-1 exceeds the upper limit of the reference range (supraphysiological) despite dose reduction
  • Fasting glucose consistently >100 mg/dL or significant increase from baseline
  • Persistent edema, joint pain, or carpal tunnel symptoms that do not resolve with dose reduction
  • Any sign of allergic reaction (urticaria, angioedema, anaphylaxis)
  • New visual changes or persistent headaches (rule out intracranial hypertension)
  • Any suspected tumor growth or new mass

Side Effects

CJC-1295

  • Water retention: Mild to moderate fluid retention is the most commonly reported side effect, particularly in the first 2 weeks. Usually self-limiting.[3]
  • Injection site reactions: Redness, induration, or mild pain at the injection site. More common with the DAC variant due to longer local depot effect.
  • Flushing and warmth: Transient facial flushing within 15–30 minutes of injection, resolving spontaneously.
  • Headache: Mild headache reported in clinical trials, typically transient.[3]
  • Blood sugar changes: Elevated fasting glucose with sustained use due to GH-mediated insulin resistance.[2]

Ipamorelin

  • Increased hunger: Ipamorelin activates the ghrelin receptor, which can stimulate appetite. This is typically mild and dose-dependent.[6]
  • Transient numbness or tingling: Paresthesias in the extremities, usually within the first 30 minutes post-injection. Self-limiting.
  • Joint stiffness: Related to GH-mediated water retention in synovial tissues. More common at higher doses.
  • Headache: Mild and transient, typically in the first week of use.
  • Lightheadedness: Occasional dizziness shortly after injection, possibly related to transient blood pressure changes.

Drug Interactions

No formal drug interaction studies have been conducted for the CJC-1295/Ipamorelin combination. The following are theoretical considerations based on known pharmacological mechanisms of GH secretagogues and the GH/IGF-1 axis:

  • Insulin and diabetes medications (metformin, sulfonylureas, SGLT2 inhibitors): GH impairs glucose tolerance and promotes insulin resistance. Concurrent use of GH secretagogues may necessitate dose adjustments of diabetes medications. Close glucose monitoring is essential.[2]
  • Glucocorticoids (prednisone, dexamethasone, hydrocortisone): Glucocorticoids reduce GH secretion and blunt the GH response to secretagogues. They also antagonize many peripheral effects of GH. Chronic glucocorticoid use may render GH secretagogue protocols less effective.[11]
  • Thyroid medications (levothyroxine, liothyronine): GH increases the peripheral conversion of T4 to T3 by upregulating type 1 deiodinase. Patients on thyroid replacement may require dose reassessment, as unmasking of central hypothyroidism can occur when GH is elevated.[12]
  • Exogenous growth hormone: Concurrent use of GH secretagogues with exogenous GH is generally redundant and increases the risk of supraphysiological IGF-1 levels. Not recommended.
  • Somatostatin analogs (octreotide, lanreotide): These directly inhibit GH release and will antagonize the effects of CJC-1295 and Ipamorelin. Contraindicated for concurrent use.

Video Resources

Growth hormone physiology and the science of GH secretagogues — Huberman Lab

Dr. Koniver on clinical GH peptide protocols including CJC-1295 and Ipamorelin — Huberman Lab

References

  1. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clinical Endocrinology. 2006;64(2):115-121. doi:10.1111/j.1365-2265.2005.02404.x. PMID: 16430706.
  2. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;30(2):152-177. doi:10.1210/er.2008-0027. PMID: 19240267.
  3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt R. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID: 16352683.
  4. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout (GHRHKO) mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00172.2006. PMID: 16822957.
  5. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702. PMID: 17018654.
  6. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID: 9849822.
  7. Gobburu JV, Agersoe H, Engell HW, Zdravkovic M, Pedersen PJ, Carr RD. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. doi:10.1023/A:1018955126402. PMID: 10496657.
  8. Bowers CY. Synergistic release of growth hormone by GHRP and GHRH. Journal of Pediatric Endocrinology. 1993;6(3-4):227-234. PMID: 8136785.
  9. Veldhuis JD, Iranmanesh A, Bowers CY. Joint mechanisms of impaired growth-hormone pulse renewal in aging men. Journal of Clinical Endocrinology & Metabolism. 2005;90(7):4177-4183. doi:10.1210/jc.2005-0336. PMID: 15870122.
  10. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8. PMID: 25331030.
  11. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717-797. doi:10.1210/edrv.19.6.0353. PMID: 9861545.
  12. Jorgensen JO, Pedersen SA, Laurberg P, Weeke J, Skakkebaek NE, Christiansen JS. Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxine-substituted central hypothyroidism. Journal of Clinical Endocrinology & Metabolism. 1989;69(6):1127-1132. doi:10.1210/jcem-69-6-1127. PMID: 2511220.